Synonyms: BCD 132 | BCD-132 | Ivlizi®
divozilimab is an approved drug (Russia (2023))
Compound class:
Antibody
Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
|
Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|